Eli Lilly and Company News Releases https://investor.lilly.com/ Eli Lilly and Company News Releases en Hurricane Season is Almost Here. Are You Ready? https://investor.lilly.com/news-releases/news-release-details/hurricane-season-almost-here-are-you-ready Lilly, Healthcare Ready and Direct Relief Helping People Prepare for Disasters, Ensure Medicines are Available INDIANAPOLIS , May 31, 2019 /PRNewswire/ -- The 2019 Atlantic hurricane season begins June 1 . With natural disasters and extreme weather on the rise, it's critical to be prepared and Fri, 31 May 2019 07:00:00 -0400 Eli Lilly and Company News Releases 41381 Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics https://investor.lilly.com/news-releases/news-release-details/lilly-announces-licensing-agreement-non-opioid-pain-asset INDIANAPOLIS , May 28, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation , a company focused on developing non-opioid, non-addictive therapeutics for the Tue, 28 May 2019 07:54:00 -0400 Eli Lilly and Company News Releases 41361 U.S. Court of Appeals Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit https://investor.lilly.com/news-releases/news-release-details/us-court-appeals-rules-favor-lilly-alimta-vitamin-regimen-patent INDIANAPOLIS , April 26, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta® (pemetrexed for injection). Fri, 26 Apr 2019 11:28:00 -0400 Eli Lilly and Company News Releases 41201 Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China https://investor.lilly.com/news-releases/news-release-details/lilly-announces-sale-legacy-antibiotics-brands-and-manufacturing INDIANAPOLIS , April 22, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor ® and Vancocin ® , as well as a manufacturing facility in Suzhou, China that produces Mon, 22 Apr 2019 22:05:00 -0400 Eli Lilly and Company News Releases 41186 Lilly and Avidity Biosciences Announce Licensing and Research Collaboration https://investor.lilly.com/news-releases/news-release-details/lilly-and-avidity-biosciences-announce-licensing-and-research -Collaboration will pursue therapeutic targets focused on immunology and other indications -Avidity to receive an upfront payment of $20 million and an investment of $15 million -Avidity eligible to receive up to approximately $405 million per target in development and commercialization milestones, Mon, 22 Apr 2019 06:30:00 -0400 Eli Lilly and Company News Releases 41166 Lilly and ImmuNext Announce Licensing and Research Collaboration https://investor.lilly.com/news-releases/news-release-details/lilly-and-immunext-announce-licensing-and-research-collaboration INDIANAPOLIS and LEBANON, N.H. , March 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and ImmuNext, Inc. today announced a global licensing and research collaboration focused on the study of a preclinical novel target that could lead to potential new medicines for autoimmune diseases by Tue, 26 Mar 2019 16:30:00 -0400 Eli Lilly and Company News Releases 41071 Lilly Announces Final Results of Elanco Exchange Offer https://investor.lilly.com/news-releases/news-release-details/lilly-announces-final-results-elanco-exchange-offer INDIANAPOLIS , March 13, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) previously owned by Lilly, which expired at Wed, 13 Mar 2019 08:48:00 -0400 Eli Lilly and Company News Releases 40986 Lilly Announces Preliminary Results of Elanco Exchange Offer https://investor.lilly.com/news-releases/news-release-details/lilly-announces-preliminary-results-elanco-exchange-offer INDIANAPOLIS , March 11, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) owned by Mon, 11 Mar 2019 06:45:00 -0400 Eli Lilly and Company News Releases 40956 Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer https://investor.lilly.com/news-releases/news-release-details/lilly-announces-final-exchange-ratio-45121-elanco-exchange-offer INDIANAPOLIS , March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) owned by Lilly. Thu, 07 Mar 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40916 Lilly Completes Acquisition of Loxo Oncology https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-loxo-oncology INDIANAPOLIS , Feb. 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology , Inc. (NASDAQ:LOXO). The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines through the addition of a Fri, 15 Feb 2019 09:23:00 -0500 Eli Lilly and Company News Releases 40671 Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health https://investor.lilly.com/news-releases/news-release-details/lilly-will-initiate-divestiture-its-remaining-interest-elanco Provides Lilly shareholders opportunity for tax-free exchange INDIANAPOLIS , Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced it will initiate an exchange offer today to divest its remaining interest in Elanco Animal Health (NYSE: ELAN). Fri, 08 Feb 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40516 Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction https://investor.lilly.com/news-releases/news-release-details/lilly-and-loxo-oncology-announce-expiration-hsr-act-waiting INDIANAPOLIS and STAMFORD, Conn. , Feb. 1, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) ("Lilly") and Loxo Oncology, Inc. (NASDAQ: LOXO) (" Loxo Oncology ") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended Fri, 01 Feb 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40271 Lilly Announces Agreement To Acquire Loxo Oncology https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-acquire-loxo-oncology INDIANAPOLIS and STAMFORD, Conn. , Jan. 7, 2019 /PRNewswire/ --  Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines through the addition of a marketed therapy and a pipeline of highly selective potential medicines for patients with genomically defined cancers. Mon, 07 Jan 2019 06:30:00 -0500 Eli Lilly and Company News Releases 40136 Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies https://investor.lilly.com/news-releases/news-release-details/lilly-and-aduro-biotech-announce-research-collaboration-and INDIANAPOLIS and BERKLEY, Calif., Dec. 18, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program for the research and development of Tue, 18 Dec 2018 16:15:00 -0500 Eli Lilly and Company News Releases 40051 Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-pre-clinical-pain-program-hydra-biosciences INDIANAPOLIS , Dec. 14, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced an agreement with Hydra Biosciences to acquire all assets related to  Hydra's pre-clinical program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is Fri, 14 Dec 2018 15:30:00 -0500 Eli Lilly and Company News Releases 40031 Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors https://investor.lilly.com/news-releases/news-release-details/lilly-and-evidation-health-expand-collaboration-analyze-data Lilly will leverage Evidation's Andromeda data platform to analyze large scale data aimed at uncovering novel digital measures of health INDIANAPOLIS and SAN MATEO, Calif. , Dec. 14, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Evidation Health , a health and measurement company that Fri, 14 Dec 2018 06:45:00 -0500 Eli Lilly and Company News Releases 40026 Lilly and AC Immune Announce License and Collaboration Agreement https://investor.lilly.com/news-releases/news-release-details/lilly-and-ac-immune-announce-license-and-collaboration-agreement INDIANAPOLIS and LAUSANNE, Switzerland , Dec. 12, 2018 /PRNewswire/ -- Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 million and Wed, 12 Dec 2018 06:00:00 -0500 Eli Lilly and Company News Releases 40001 Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines https://investor.lilly.com/news-releases/news-release-details/lilly-and-nextcure-announce-collaboration-discover-and-develop INDIANAPOLIS and BELTSVILLE, Md. , Nov. 5, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and NextCure, Inc. today announced a multi-year collaboration focused on the discovery and development of immuno-oncology therapies. The collaboration seeks to discover novel cancer targets utilizing Mon, 05 Nov 2018 16:30:00 -0500 Eli Lilly and Company News Releases 39806 Lilly and Dicerna Announce RNAi Licensing and Research Collaboration https://investor.lilly.com/news-releases/news-release-details/lilly-and-dicerna-announce-rnai-licensing-and-research - Companies will collaborate on RNAi research for cardio-metabolic, neurodegeneration and pain targets - Dicerna to receive an upfront payment of $100 million and an equity investment of $100 million - Dicerna eligible to receive up to approximately $350 million per target in development and Mon, 29 Oct 2018 06:00:00 -0400 Eli Lilly and Company News Releases 39786 Karen Walker Elected to Lilly Board of Directors https://investor.lilly.com/news-releases/news-release-details/karen-walker-elected-lilly-board-directors INDIANAPOLIS , Oct. 16, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Karen Walker as a new member, effective December 1, 2018 . As a member of Lilly's board, she will serve on both the Audit Committee and the Public Policy and Compliance Committee. Tue, 16 Oct 2018 06:45:00 -0400 Eli Lilly and Company News Releases 39741 Anne White Promoted to President of Lilly Oncology https://investor.lilly.com/news-releases/news-release-details/anne-white-promoted-president-lilly-oncology INDIANAPOLIS , Aug. 30, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that Anne White has been promoted to senior vice president of Lilly and president of Lilly Oncology effective September 1, 2018 . She will become a member of Lilly's executive committee, reporting Thu, 30 Aug 2018 17:00:00 -0400 Eli Lilly and Company News Releases 39431 Elanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes https://investor.lilly.com/news-releases/news-release-details/elanco-animal-health-announces-pricing-20-billion-senior-notes INDIANAPOLIS , Aug. 14, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health Incorporated , has priced a private offering of $2.0 billion of senior notes (the "Offering"), consisting of $500 million aggregate principal amount of 3.912 Tue, 14 Aug 2018 21:25:00 -0400 Eli Lilly and Company News Releases 39376 Elanco Animal Health Files IPO Registration Statement https://investor.lilly.com/news-releases/news-release-details/elanco-animal-health-files-ipo-registration-statement INDIANAPOLIS , Aug. 2, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health , has filed a registration statement with the U.S. Securities and Exchange Commission ( SEC ) for an initial public offering (IPO) of common stock. Thu, 02 Aug 2018 17:40:00 -0400 Eli Lilly and Company News Releases 39331 Lilly to Separate Elanco Animal Health with Initial Public Offering https://investor.lilly.com/news-releases/news-release-details/lilly-separate-elanco-animal-health-initial-public-offering INDIANAPOLIS , July 24, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that the company has completed its strategic review of Elanco Animal Health , and will file a registration statement in the coming weeks with the U.S. Securities and Exchange Commission ( SEC ) for a Tue, 24 Jul 2018 06:20:00 -0400 Eli Lilly and Company News Releases 39276 U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit https://investor.lilly.com/news-releases/news-release-details/us-district-court-rules-favor-lilly-alimta-vitamin-regimen INDIANAPOLIS , June 22, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly that the Alimta ® (pemetrexed for injection) vitamin regimen patent would be infringed by a competitor that had Fri, 22 Jun 2018 15:49:00 -0400 Eli Lilly and Company News Releases 39126 Lilly Completes Acquisition of ARMO BioSciences https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-armo-biosciences INDIANAPOLIS , June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (NASDAQ: ARMO). Lilly's tender offer for all outstanding shares of common stock of ARMO, at a price of $50.00 per share in cash, Fri, 22 Jun 2018 08:31:00 -0400 Eli Lilly and Company News Releases 39116 Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer by TRC Capital Corp. https://investor.lilly.com/news-releases/news-release-details/lilly-recommends-shareholders-reject-below-market-mini-tender INDIANAPOLIS , June 5, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) has learned of an unsolicited mini-tender offer by TRC Capital Corp. for the purchase of up to 1.5 million shares of Lilly common stock at $81.00 per share. Lilly does not endorse TRC Capital's offer. Tue, 05 Jun 2018 14:53:00 -0400 Eli Lilly and Company News Releases 39031 Sue Mahony to Retire as President of Lilly Oncology https://investor.lilly.com/news-releases/news-release-details/sue-mahony-retire-president-lilly-oncology Mahony will continue in position through August 31, successor named at a later date INDIANAPOLIS , May 23, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today that Sue Mahony , Ph.D., senior vice president of Lilly and president of Lilly Oncology, will retire at the end of Wed, 23 May 2018 14:00:00 -0400 Eli Lilly and Company News Releases 38941 Lilly to Acquire AurKa Pharma https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-aurka-pharma Acquisition Expands Lilly Oncology Pipeline with Early-Phase Asset Being Studied in Multiple Tumor Types INDIANAPOLIS , May 14, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire AurKa Pharma, Inc. , a company established by TVM Capital Life Science to Mon, 14 May 2018 07:44:00 -0400 Eli Lilly and Company News Releases 38901 Lilly Announces Agreement To Acquire ARMO BioSciences https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-acquire-armo-biosciences $1.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types INDIANAPOLIS and REDWOOD CITY, Calif. , May 10, 2018 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. Thu, 10 May 2018 07:30:00 -0400 Eli Lilly and Company News Releases 38876